Drug Eluting Stent System
Elixir Medical is developing a wide range of device platforms for vascular therapies. These include coronary stent systems, small vessel coronary stent systems, drug eluting stent systems and fully bioabsorbable drug eluting stent systems.
USA | International
Novolimus
Novolimus™ is a novel mTOR inhibitor macrocyclic lactone with anti-proliferative and immunosuppresive properties designed for drug eluting stent therapy.
Novolimus DES System
Elixir's first coronary drug eluting stent is designed with durable polymer coating technology to control the release of Novolimus over a period of time. This polymer has prior history of human use on implantable devices. The Novolimus eluting stent system is designed to provide safety and efficacy with a substantially lower polymer load and lower drug dose than current commercially available drug eluting stent systems.
EXCELLA First-in-Man Clinical Trial
The Novolimus eluting stent system is being evaluated in the EXCELLA feasibility clinical trial. The primary endpoint of the study is four-month angiographic late loss. Secondary endpoints included IVUS analysis at follow-up.